Dr. Reddy's Laboratories unveils Atomoxetine Capsules, USP in the US Market
31 October 2018 -

Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Wednesday the availability of Atomoxetine Capsules, USP in the US market.

In addition, the company's Atomoxetine Capsules, USP is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg with 30 counts bottle size. Atomoxetine is used to treat attention-deficit hyperactivity disorder (ADHD), including psychological, social, and other treatments. It may help to increase the ability to pay attention, concentrate, stay focused and stop fidgeting.

The company said the US Food and Drug Administration (USFDA) approved Atomoxetine Capsules, USP, is the therapeutic equivalent generic version of Strattera (atomoxetine) Capsules. Straterra is a registered trademark of Eli Lilly and Company.

For the most recent 12 months ending in August 2018, the Strattera brand and generic had US sales of about USD304m MAT, according to IMS Health.